A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Phase 2 Recruiting 30 enrolled Vertex Pharmaceuticals Incorporated

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).

Timeline

Start: 2026-05-13
Primary completion: 2029-03-02
Completion: 2029-03-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Povetacicept	Protein / enzyme biologic	—	Subcutaneous

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Summary

Timeline

Drugs

Indications